Evidence map›Paper›PMID 27822684›Full record

Trial reportGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2017

Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin.

Kazuhiro Nishikawa, Yasuhide Yamada, Kenji Ishido, Masahiro Gotoh, Hideaki Bando, Naotoshi Sugimoto, Tomohiro Nishina, Kenji Amagai, Keisho Chin, Yasumasa Niwa and 12 more

Open access · bronzeAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 20 institutions in 1 country.

Kazuhiro NishikawaDepartment of Surgery, National Hospital Organization Osaka National Hospital, 2-1-14, Hoenzaka, Chuo-ku, Osaka, 540-0006, Japan. kazuno13@hotmail.co.jp.
Yasuhide YamadaGastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
Kenji IshidoDepartment of Gastroenterology, Kitasato University East Hospital, Sagamihara, Japan.
Masahiro GotohCancer Chemotherapy Center, Osaka Medical College Hospital, Takatsuki, Japan.
Hideaki BandoDivision of Gastrointestinal Oncology and Digestive Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Naotoshi SugimotoDepartment of Clinical Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
Tomohiro NishinaDepartment of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Kenji AmagaiDepartment of Gastroenterology, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Keisho ChinDepartment of Gastroenterology, Cancer Institute Hospital of JFCR, Tokyo, Japan.
Yasumasa NiwaDepartment of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan.
Akihito TsujiDepartment of Medical Oncology, Kochi Health Sciences Center, Kochi, Japan.
Hiroshi ImamuraDepartment of Surgery, Sakai City Hospital, Sakai, Japan.
Masahiro TsudaDepartment of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan.
Hirofumi YasuiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-Gun, Japan.
Hirofumi FujiiDivision of Clinical Oncology, Jichi Medical University, Shimotsuke, Japan.
Kensei YamaguchiDivision of Gastroenterology, Saitama Cancer Center, Kita-Adachi-Gun, Japan.
Hisateru YasuiDepartment of Medical Oncology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Shuichi HironakaClinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan.
Ken ShimadaDepartment of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan.
Hiroto MiwaDivision of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Chikuma HamadaFaculty of Engineering, Tokyo University of Science, Tokyo, Japan.
Ichinosuke HyodoDivision of Gastroenterology, University of Tsukuba, Tsukuba, Japan.
Shizuoka Cancer Center · JPAichi Cancer Center · JPChiba Cancer Center · JPHyogo Medical University · JPHyogo Prefectural Cancer Center · JPIbaraki Prefectural Central Hospital · JPJichi Medical University · JPKitasato University East Hospital · JPKochi Medical School Hospital · JPNational Cancer Center Hospital East · JPOsaka Medical and Pharmaceutical University · JPOsaka Medical Center for Cancer and Cardiovascular Diseases · JPOsaka National Hospital · JPSaitama Cancer Center · JPSakai Municipal Hospital · JPShikoku Cancer Center · JPShowa University Northern Yokohama Hospital · JPThe Cancer Institute Hospital · JPTokyo University of Science · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe association between progression type and survival has been reported in breast cancer, but remains unclear in advanced gastric cancer (AGC). Here, this association was assessed using data obtained from an earlier randomized phase III study demonstrating the non-inferiority of S-1 plus oxaliplatin (SOX) to S-1 plus cisplatin (CS) on progression-free survival and overall survival (OS) in the first-line treatment of AGC.

methodsA Cox regression model including two time-dependent covariates, progression with new lesions and with no new lesions, was used to determine their effect on OS in each treatment group. When both types of progression were detected simultaneously, this was categorized as progression with new lesions.

resultsProgression with and with no new lesions was identified in 91 and 167 patients, respectively, in the SOX group (333 patients) and 95 and 147 patients, respectively, in the CS group (330 patients). The association between progression type and OS was similar in both treatment groups; both progression types were strong poor prognostic factors, particularly progression with new lesions [hazard ratio (HR), 7.26; 95% confidence interval (CI), 4.89-10.80 in SOX and HR, 5.78; 95% CI, 4.13-8.08 in CS] compared to no new lesions (HR, 4.66; 95% CI, 3.21-6.77 in SOX and HR, 2.71; 95% CI, 1.95-3.75 in CS).

conclusionsProgression accompanied by new lesions had a strong negative impact on OS in patients treated with S-1 and platinum for AGC.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinDisease-Free SurvivalDisease ProgressionDrug CombinationsFemaleHumansMaleMiddle AgedOrganoplatinum CompoundsOxaliplatinOxonic AcidProportional Hazards ModelsStomach NeoplasmsCisplatinDrug CombinationsOrganoplatinum CompoundsOxaliplatinOxonic AcidS 1 (combination)TegafurGastric cancerOverall survivalProgression-free survivalProgression typeS-1 plus oxaliplatin

Identifiers

PMID27822684
OpenAlexW2556311539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.